2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.25 Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/metastatic NSCLC

EP.11A.25 Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/metastatic NSCLC

Back to course

Pdf Summary

This study, presented by Umit Tapan at the World Congress on Lung Cancer (WCLC) in September 2024, aimed to establish a consensus on first-line maintenance treatment (1LMT) for advanced/metastatic non-small cell lung cancer (a/mNSCLC) following a pembrolizumab-containing first-line (1L) regimen. Using the Delphi method, a panel of oncologists from the US, UK, France, and Germany was involved in three survey rounds conducted between June 2023 and January 2024. The survey sought consensus on when and how 1LMT should be applied, considering factors like the patient's response to 1L treatment, histology, ECOG performance status, and comorbidities.<br /><br />Key findings include:<br />- Oncologists generally agreed that 1LMT should follow 4–6 cycles of pembrolizumab-containing induction.<br />- Consensus was reached that 1LMT should be considered for patients showing complete response (CR), partial response (PR), or stable disease (SD) after 1L induction, though not for patients whose disease progressed.<br />- Oncologists concurred that ECOG performance scores of 0, 1, or 2 warranted continuation of 1LMT, irrespective of histology, but advised against it for scores of 3 or 4.<br />- No consensus was reached regarding 1LMT recommendations for patients with PD-L1 levels of 50% or on pemetrexed duration.<br /><br />The study highlights challenges due to varying international guidelines and emphasizes important factors for consideration in 1LMT decisions, though financial considerations did not reach consensus. Despite these challenges, this study offers valuable insights into the treatment of a/mNSCLC, potentially guiding clinicians amid diverse clinical practice guidelines.

Asset Subtitle

Umit Tapan

Meta Tag

Speaker Umit Tapan

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

World Congress on Lung Cancer

Umit Tapan

non-small cell lung cancer

first-line maintenance treatment

pembrolizumab

Delphi method

oncologists

ECOG performance status

PD-L1 levels

clinical practice guidelines